An mRNA vaccine with broad-spectrum neutralizing protection against Omicron variant sublineages BA.4/5 -included SARS-CoV-2.

Sang, Ye; Zhang, Zhen; Li, Entao; Lu, Haitao; Long, Jinrong; Cao, Yiming; Yu, Changxiao; Wang, Tiecheng; Yang, Jing; Wang, Shengqi

Sang, Ye; Zhang, Zhen; Li, Entao; Lu, Haitao; Long, Jinrong; Cao, Yiming; Yu, Changxiao; Wang, Tiecheng; Yang, Jing; Wang, Shengqi.

Afiliação

Sang Y; Beijing Institute of Microbiology and Epidemiology, Beijing, 100850, China.
Zhang Z; School of Life Science, University of Hebei, Baoding, 071002, China.
Li E; Beijing Institute of Microbiology and Epidemiology, Beijing, 100850, China.
Lu H; School of Life Science, University of Hebei, Baoding, 071002, China.
Long J; Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, 130000, China.
Cao Y; Beijing Institute of Microbiology and Epidemiology, Beijing, 100850, China.
Yu C; Beijing Institute of Microbiology and Epidemiology, Beijing, 100850, China.
Wang T; Beijing Institute of Microbiology and Epidemiology, Beijing, 100850, China.
Yang J; Beijing Institute of Microbiology and Epidemiology, Beijing, 100850, China.
Wang S; Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, 130000, China. wgcha@163.com.

Signal Transduct Target Ther ; 7(1): 362, 2022 10 11.

Article em En | MEDLINE | ID: mdl-36220820

Assuntos

COVID-19; SARS-CoV-2; COVID-19/prevenção & controle; Humanos; SARS-CoV-2/genética; Vacinas Sintéticas/genética; Vacinas de mRNA

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans Idioma: En Revista: Signal Transduct Target Ther Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China País de publicação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google